Full-Time

VNS Territory Manager

Epilepsy

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$85k - $100k/yr

+ Commission

Seattle, WA, USA + 2 more

More locations: Olympia, WA, USA | Tacoma, WA, USA

In Person

Must reside within Western Washington including Wenatchee; up to 40% travel with occasional 2-3 day overnight trips.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Inventory Management
Data Analysis

Get referred to LivaNova

See people who can refer or advise you

Requirements
  • Strong work ethic, with a resilient results orientation
  • Minimum 3 to 5 years of successful selling experience in a medical field, preferably in a consultative role (e.g. Medical Device and Pharma sales), where daily accountabilities are established, measured and rewarded
  • Demonstrated aptitude and success in fostering solid, value-based physician relationships, and a capacity for interacting with patients in a clinical environment
  • Solid process orientation, demonstrated resource management / allocation experience, and the ability to perform multiple tasks simultaneously
  • Intellectual capacity to interpret trends and data, translating the information into actions and improvements
  • Self starter and independent thinker, with the aptitude to work autonomously
  • Robust interpersonal skills, with evidence of teamwork and collaboration
  • Exceptional written and verbal communication skills, with customers and patients at all levels
  • Creative thinking
  • Demonstrated commitment towards LivaNova mission
  • BS/BA degree, preferably in life sciences, nursing, allied health, or business
Responsibilities
  • Achieve or exceed sales objectives and be accountable for daily management of Territory.
  • Engage onsite with epileptologists, neurologists, and neuroscientists with latest therapy information, clinical studies, etc. leading to patient identifications.
  • Uncover barriers to VNS Therapy adoption and develop actions and plans to address and overcome the barriers, as appropriate.
  • Build and maintain productive professional relationships with customers.
  • Build value proposition with surgeons to create surgical capacity appropriate for patient demand.
  • Create, maintain, and execute cross-functional physician targeting plans to achieve quarterly goals and long-term strategy.
  • Educate referring physicians in non-Key Account CEC’s and community accounts about current DRE treatment gaps, quality measures, and available LIVN resources.
  • Conduct on-site product demonstrations.
  • Educate and train fellows / residents on DRE treatments and VNS Therapy.
  • Provide onsite post-implant education of VNS Therapy and product support and education to staff, patients, and families.
  • Regularly educate and update physicians/clinicians and clinic follow-up staff on new product releases of device systems and features, including both hardware and software modifications.
  • Demonstrate outstanding product and therapy knowledge.
  • Demonstrate a clinical aptitude to appropriately challenge providers and change prescriber treatment selection.
  • Receives technical inquiries and provides solutions to questions or problems
  • Provide onsite surgical case coverage, follow-up support and troubleshooting of VNS Therapy in non-Key Account CEC’s and community accounts.
  • Provide onsite technical support, as requested by physicians, during dosing appointments.
  • Obtain PIQ and/or PAF from patients, caregivers and physicians.
  • Work with buying managers to negotiate pricing and deals, manage inventory and secure orders.
  • Regularly monitor account performance, identify issues, and mitigate risks proactively.
  • Participate in professional outreach programs (e.g., neurology conferences)
  • Support DRE education programs, as directed.
  • Coordinate with case management for patient education and account interactions needed to support patients as they navigate their path to VNS Therapy.
  • Lead weekly territory team meetings to review progress towards quarterly goals and long-term strategy.
  • Lead weekly physician targeting meetings with regional manager to review progress towards quarterly goals and long-term strategy.
  • Build solid customer relationships.
  • Demonstrate outstanding product knowledge.
  • Implement routing/targeted call plan.
  • Complete administrative requirements on time and accurately.
  • Maintain company standards involving ethical and moral character while professionally representing the company.
  • Perform other duties as may be required by management.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $390.6 million, with 10.8% reported growth and raised guidance.
  • PolySync lifted OSA response to 84.5%, supporting commercial conversion from nonresponders.
  • LivaNova plans a 2027 MRI-compatible aura6000 launch, extending its sleep franchise.

What critics are saying

  • SNIA environmental liability stands at €337.8 million, despite a €157.3 million reversal.
  • 3T device litigation still covers about 65 claims worldwide and drains management time.
  • Third-party component shortages constrain Essenz expansion, risking share loss to Getinge and Medtronic.

What makes LivaNova unique

  • Essenz heart-lung systems and consumables anchor LivaNova's cardiopulmonary moat across hospitals.
  • aura6000 became the first U.S.-approved hypoglossal therapy without collapse warning language in March 2026.
  • CORE-VNS showed 80% median seizure reduction at 36 months, strengthening epilepsy credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Jun 16th, 2026
LivaNova's PolySync programming achieves 84.5% response rate in obstructive sleep apnoea study

LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.

Business Wire
Jun 11th, 2026
Jette Nygaard-Andersen joins LivaNova board as medtech company reshuffles directors

LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.

Yahoo Finance
May 6th, 2026
LivaNova posts 10% organic growth in Q2 driven by cardiopulmonary momentum and neuromodulation gains

LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.

Yahoo Finance
May 6th, 2026
LivaNova posts 13% organic revenue growth in Q3, driven by cardiopulmonary surge and epilepsy gains

LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.

Yahoo Finance
May 6th, 2026
LivaNova beats Q1 expectations with $362.3M revenue but shares slip 2% on cautious guidance

LivaNova reported first-quarter results that exceeded Wall Street expectations, but shares fell more than 2% in premarket trading as investors reacted cautiously to guidance. The medical technology company posted adjusted earnings per share of $0.98, beating analyst estimates of $0.90, whilst revenue reached $362.3 million, surpassing the $346.06 million consensus. The company raised its full-year 2026 revenue growth guidance to 7.0%–8.0% on a constant-currency basis, up from 6.0%–7.0% previously. Adjusted diluted EPS guidance increased to $4.20–$4.30 from $4.15–$4.25. However, the $4.25 midpoint only marginally exceeded analyst consensus of $4.21. Revenue growth was driven by the Cardiopulmonary division, which rose 18.3% to $208.7 million, and Neuromodulation, which climbed 9.3% to $151.8 million.